B-cell concentration changes when switching from IV anti-CD20 antibodies to ofatumumab in MS: OLIKOS
Автор: VJNeurology
Загружено: 2026-02-25
Просмотров: 21
Описание:
Le Hanh Hua, MD, Cleveland Clinic, Las Vegas, NV, discusses the results of the Phase III OLIKOS study (NCT04486716), which found that efficacy and safety were maintained when switching from IV anti-CD20 therapies to subcutaneous ofatumumab for multiple sclerosis (MS). Dr Hua then goes on to share details of a secondary analysis investigating changes in B-cell concentrations. This interview is part of our coverage of the 11th Annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
